140 related articles for article (PubMed ID: 17040116)
1. Pioglitazone/metformin.
Deeks ED; Scott LJ
Drugs; 2006; 66(14):1863-77; discussion 1878-80. PubMed ID: 17040116
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone/Metformin.
Wellington K
Drugs; 2005; 65(11):1581-92; discussion 1593-4. PubMed ID: 16033298
[TBL] [Abstract][Full Text] [Related]
5. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
Seufert J
Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
[TBL] [Abstract][Full Text] [Related]
6. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.
Derosa G; Tinelli C; Maffioli P
Diabetes Obes Metab; 2009 Dec; 11(12):1091-9. PubMed ID: 19765050
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
Perez A; Zhao Z; Jacks R; Spanheimer R
Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone: a review of its use in type 2 diabetes mellitus.
Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
[TBL] [Abstract][Full Text] [Related]
9. Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet.
Karim A; Slater M; Bradford D; Schwartz L; Laurent A
J Clin Pharmacol; 2007 Jan; 47(1):48-55. PubMed ID: 17192501
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone and metformin.
Hill NR; Matthews DR
Drugs Today (Barc); 2007 Jul; 43(7):443-54. PubMed ID: 17728845
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
[TBL] [Abstract][Full Text] [Related]
14. Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug.
Karim A; Slater M; Bradford D; Schwartz L; Zhao Z; Cao C; Laurent A
J Clin Pharmacol; 2007 Jan; 47(1):37-47. PubMed ID: 17192500
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
Neeser K; Lübben G; Siebert U; Schramm W
Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes.
Perez A; Khan M; Johnson T; Karunaratne M
Diab Vasc Dis Res; 2004 May; 1(1):44-50. PubMed ID: 16305056
[TBL] [Abstract][Full Text] [Related]
20. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
